TearScience® is the only company dedicated to identifying, diagnosing, and treating MGD, the leading cause of dry eye, with an FDA-cleared solution that restores gland function.
TearScience® was founded in 2005 and is dedicated to the innovation of revolutionary Evaporative Dry Eye/ Meibomian Gland Dysfunction assessments and treatment. With approximately 90% of Dry Eye attributed to Meibomian Gland Dysfunction (MGD) and 300 million dry eye sufferers worldwide, MGD represents one of the largest patient segments found within eye care practices. MGD is prevalent, chronic and progressive. By detecting, educating staff and patients, and treating MGD, the root cause of dry eye, eye care professionals can now effectively and safely intervene in the progression of MGD, improve gland function, and alleviate symptoms.
Dr. Donald Korb, co-founder of TearScience® has dedicated over 30 years to research into the role and importance of meibomian glands, adding to the work of giants in the field, and then named the dysfunction MGD along with Professor Henriquez in 1980. Throughout his long career Dr. Korb discovered and named ten ocular clinical entities. has been granted over 45 patents related to medical technologies and products, and published over 100 peer-reviewed articles. His recent work included significant input from Caroline Blackie OD, MSc and Steve Grenon, VP of R&D. The TearScience® management team includes world-class engineers involved in several previous significant technological accomplishments. The team employs science, collaborative problem solving, and project management expertise to deliver the first solution for the systematic detection and effective treatment of MGD.